Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Issued (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Shares Issued for 6 consecutive years, with $181000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 85.5% to $181000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $365000.0 through Dec 2025, down 70.75% year-over-year, with the annual reading at $365000.0 for FY2025, 70.75% down from the prior year.
  • Shares Issued hit $181000.0 in Q4 2025 for Lyell Immunopharma, down from $184000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $391.8 million in Q3 2021 to a low of -$391.8 million in Q4 2021.
  • Historically, Shares Issued has averaged $26.4 million across 5 years, with a median of $184000.0 in 2025.
  • Biggest YoY gain for Shares Issued was 1119334.29% in 2021; the steepest drop was 1119334.29% in 2021.
  • Year by year, Shares Issued stood at -$391.8 million in 2021, then surged by 100.16% to $632000.0 in 2022, then crashed by 235.6% to -$857000.0 in 2023, then soared by 245.62% to $1.2 million in 2024, then tumbled by 85.5% to $181000.0 in 2025.
  • Business Quant data shows Shares Issued for LYEL at $181000.0 in Q4 2025, $184000.0 in Q2 2025, and $1.2 million in Q4 2024.